Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder

NCT07010302 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07010302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07010302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder
Lead sponsor
Massachusetts General Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
September 1, 2026
Completion date
May 31, 2030
Enrollment
540 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

nmosd